2025 年 9 月 12 日- 上午 11:23
蒙特利尔，2025 年 9 月 12 日（GLOBE NEWSWIRE）-- Theratechnologies Inc.（“ Theratechnologies” 或 “ 公司”）（TSX:TH）（NASDAQ:THTX），一家商业阶段的生物制药公司，欣然宣布其股东已批准之前宣布的安排计划（“ 安排”），该计划根据《商业公司法》（魁北克）第 XVI 章第 II 节涉及 CB Biotechnology, LLC（“ 买方”），其为 Future Pak, LLC（“ Future Pak”）的关联公司。
在今天早些时候举行的 Theratechnologies 特别股东会议上，安排决议获得 97.44% 的投票支持，投票者为亲自或虚拟出席会议的股东，或通过代理人代表出席会议的股东，排除根据《多边工具 61-101 – 保护少数证券持有者在特殊交易中的权益》要求排除的股东投票后，获得 97.43% 的投票支持。
拟议的安排仍需满足某些惯例的成交条件，包括在预计于 2025 年 9 月 16 日举行的听证会后，由魁北克高等法院发布最终命令。
关于 Theratechnologies
Theratechnologies（TSX: TH）（NASDAQ: THTX）是一家专注于商业化创新疗法的专业生物制药公司，这些疗法有潜力重新定义护理标准。有关 Theratechnologies 的更多信息，请访问其网站 www.theratech.com，或在 SEDAR+ 上访问 www.sedarplus.ca，或在 EDGAR 上访问 www.sec.gov。请在 LinkedIn 和 X 上关注 Theratechnologies。
关于 Future Pak
Future Pak 成立于 1977 年，总部位于密歇根州维克索姆，连同其附属公司，是一家私营合同制造商、包装商和药品及营养保健品的分销商。Future Pak 在零售、专业和机构市场运营，利用其强大的基础设施和合作伙伴网络提供以质量为先、以患者为中心的解决方案。
前瞻性信息
本新闻稿包含前瞻性声明和前瞻性信息（统称为 “ 前瞻性声明”），根据适用的证券法，这些声明基于我们管理层的信念和假设以及当前可用的信息。您可以通过 “可能”、“将”、“如果”、“应该”、“能够”、“有希望”、“会”、“展望”、“相信”、“计划”、“设想”、“预期”、“期待” 和 “估计” 等术语，或这些术语的否定形式或变体来识别前瞻性声明。本新闻稿中包含的前瞻性声明包括但不限于预计收到最终命令的日期。
这些前瞻性声明表达了截至本新闻稿日期，公司对未来事件或结果的估计、预测、展望、期望或意见，以及公司认为在特定情况下适当的其他假设，包括但不限于对各方能够及时以满意条款获得所需法院批准的假设；各方能够及时满足成交的其他条件以及完成安排的假设；以及其他与实施安排所需步骤相关的期望和假设。尽管公司相信这些前瞻性声明所产生的期望是基于有效和合理的基础和假设，但这些前瞻性声明本质上受到重要风险和不确定性的影响，其中许多超出了公司的控制，因此实际结果可能与这些前瞻性声明中披露或暗示的结果有显著差异。可能导致实际结果和未来事件与当前表达的期望显著不同的重要风险和不确定性包括但不限于：安排可能无法按照当前设想的相同条款和条件或时间完成，甚至可能根本无法完成，原因可能包括未能及时获得或满足所需的法院批准和其他成交条件，或其他原因；买方完成与安排相关的预期债务融资的能力；公司未能实现与 CVR 相关的任何里程碑；围绕安排的不确定性可能对公司保留客户、商业伙伴和关键员工产生不利影响；第三方提出收购提案的可能性；与税务事项相关的风险；公司开展的业务固有的其他风险以及超出其控制范围的因素，这些因素可能对公司或其完成安排的能力产生重大不利影响；以及一般经济条件，包括关税的潜在影响。
有关公司业务的其他风险和不确定性，请参见公司 2024 年年度管理和讨论分析中的 “财务风险管理” 和 “风险因素” 部分，该分析可在公司在 SEDAR+ 上的发行人资料中找到，网址为 www.sedarplus.ca，以及公司 20-F 表格中 “关键信息” 标题下的 “风险因素” 部分，该表格可在公司在 EDGAR 上的发行人资料中找到，网址为 https://www.sec.gov/edgar/search。读者应仔细考虑 “风险因素” 部分所列事项。读者需注意，前述因素列表并不详尽，且不应过度依赖前瞻性声明。因此，读者被告知，实际结果可能与预期结果存在重大差异。除非适用的证券法另有要求，公司明确声明不打算，也不承担更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。
如需更多信息，请联系：
Theratechnologies Inc.
投资者咨询：
Philippe Dubuc
高级副总裁兼首席财务官
pdubuc@theratech.com
438-315-6608
媒体咨询：
Julie Schneiderman
高级总监，传播与企业事务
communications@theratech.com
514-336-7800
Future Pak
投资者和媒体可联系 media@futurepak.com。
<img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU9ERTVNeU0zTVRRME16ZzNJekl3T0RNek9ETT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU9ERTVNeU0zTVRRME16ZzNJekl3T0RNek9ETT0"/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmRhMGMzNGYtOGY2Yi00OWVkLTk4NmQtNTQ3NmRiMTE3MzBjLTEwOTQ5NTQtMjAyNS0wOS0xMi1lbg==/tiny/Theratechnologies.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmRhMGMzNGYtOGY2Yi00OWVkLTk4NmQtNTQ3NmRiMTE3MzBjLTEwOTQ5NTQtMjAyNS0wOS0xMi1lbg==/tiny/Theratechnologies.png"/>

THTX

Theratechnologies Inc. 的股东已批准与 Future Pak 的收购安排计划，投票支持率为 97.44%。该安排需满足惯常的成交条件，包括预计于 2025 年 9 月 16 日获得魁北克高等法院的最终裁定。Theratechnologies 是一家专注于创新疗法的生物制药公司，而 Future Pak 是一家制药产品的合同制造商和分销商。该安排的完成可能面临风险和不确定性，包括法院批准和融资问题

09/12/2025 - 11:23 AM
<div class="lb-trans">2025 年 9 月 12 日- 上午 11:23
</div>MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“ Theratechnologies” or the“ Company”) (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement (the“ Arrangement”) under ChapterXVI – DivisionII of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “ Purchaser”), an affiliate of Future Pak, LLC (“ Future Pak”).
<div class="lb-trans">蒙特利尔，2025 年 9 月 12 日（GLOBE NEWSWIRE）-- Theratechnologies Inc.（“ Theratechnologies” 或 “ 公司”）（TSX:TH）（NASDAQ:THTX），一家商业阶段的生物制药公司，欣然宣布其股东已批准之前宣布的安排计划（“ 安排”），该计划根据《商业公司法》（魁北克）第 XVI 章第 II 节涉及 CB Biotechnology, LLC（“ 买方”），其为 Future Pak, LLC（“ Future Pak”）的关联公司。
</div>At the special meeting of shareholders of Theratechnologies held earlier today, the arrangement resolution was approved by 97.44% of the votes cast by the holders of shares present in person or virtually or represented by proxy at the meeting, and by 97.43% of the votes cast by the holders of shares present in person or virtually or represented by proxy at the meeting, excluding the votes cast by the shareholders required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions.
<div class="lb-trans">在今天早些时候举行的 Theratechnologies 特别股东会议上，安排决议获得 97.44% 的投票支持，投票者为亲自或虚拟出席会议的股东，或通过代理人代表出席会议的股东，排除根据《多边工具 61-101 – 保护少数证券持有者在特殊交易中的权益》要求排除的股东投票后，获得 97.43% 的投票支持。
</div>The proposed arrangement remains subject to certain customary closing conditions, including the issuance of a final order by the Superior Court of Québec following the hearing expected to take place on September16, 2025.
<div class="lb-trans">拟议的安排仍需满足某些惯例的成交条件，包括在预计于 2025 年 9 月 16 日举行的听证会后，由魁北克高等法院发布最终命令。
</div>About Theratechnologies
<div class="lb-trans">关于 Theratechnologies
</div>Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on its website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on LinkedIn and X.
<div class="lb-trans">Theratechnologies（TSX: TH）（NASDAQ: THTX）是一家专注于商业化创新疗法的专业生物制药公司，这些疗法有潜力重新定义护理标准。有关 Theratechnologies 的更多信息，请访问其网站 www.theratech.com，或在 SEDAR+ 上访问 www.sedarplus.ca，或在 EDGAR 上访问 www.sec.gov。请在 LinkedIn 和 X 上关注 Theratechnologies。
</div>About Future Pak
<div class="lb-trans">关于 Future Pak
</div>Founded in 1977 and headquartered in Wixom, Michigan, Future Pak, along with its affiliates, is a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products. Future Pak operates across retail, specialty and institutional markets, leveraging its robust infrastructure and partner network to deliver quality-first, patient-centric solutions.
<div class="lb-trans">Future Pak 成立于 1977 年，总部位于密歇根州维克索姆，连同其附属公司，是一家私营合同制造商、包装商和药品及营养保健品的分销商。Future Pak 在零售、专业和机构市场运营，利用其强大的基础设施和合作伙伴网络提供以质量为先、以患者为中心的解决方案。
</div>Forward-Looking Information
<div class="lb-trans">前瞻性信息
</div>This press release contains forward-looking statements and forward-looking information (collectively,“ Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as “may”, “will”, “if”, “should”, “could”, “promising”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, the anticipated date for the receipt of the final order.
<div class="lb-trans">本新闻稿包含前瞻性声明和前瞻性信息（统称为 “ 前瞻性声明”），根据适用的证券法，这些声明基于我们管理层的信念和假设以及当前可用的信息。您可以通过 “可能”、“将”、“如果”、“应该”、“能够”、“有希望”、“会”、“展望”、“相信”、“计划”、“设想”、“预期”、“期待” 和 “估计” 等术语，或这些术语的否定形式或变体来识别前瞻性声明。本新闻稿中包含的前瞻性声明包括但不限于预计收到最终命令的日期。
</div>These Forward-Looking Statements express, as of the date of this press release, the estimates, predictions, projections, expectations, or opinions of the Company about future events or results, as well as other assumptions, both general and specific, that the Company believes are appropriate in the circumstances, including but not limited to assumptions as to the ability of the parties to receive, in a timely manner and on satisfactory terms, the required court approval; the ability of the parties to satisfy, in a timely manner, the other conditions to the closing and the completion of the Arrangement; and other expectations and assumptions concerning the steps required to give effect to the Arrangement. Although the Company believes that the expectations produced by these Forward-Looking Statements are founded on valid and reasonable bases and assumptions, these Forward-Looking Statements are inherently subject to important risks and uncertainties, many of which are beyond the Company’s control, such that actual results may differ significantly from those that are disclosed in or implied by such Forward-Looking Statements. The important risks and uncertainties that may cause the actual results and future events to differ significantly from the expectations currently expressed include, but are not limited to: the possibility that the Arrangement will not be completed on the same terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, the required court approval and other conditions to the closing of the Arrangement or for other reasons; the Purchaser’s ability to complete its anticipated debt financing relating to the Arrangement; the failure by the Company to achieve any milestones relating to the CVRs; the uncertainty surrounding the Arrangement could adversely affect the Company’s retention of customers, business partners and key employees; the potential for a third party to make an acquisition proposal; risks related to tax matters; other risks inherent to the business carried out by the Company and factors beyond its control which could have a material adverse effect on the Company or its ability to complete the Arrangement; and general economic conditions, including the potential impact of tariffs.
<div class="lb-trans">这些前瞻性声明表达了截至本新闻稿日期，公司对未来事件或结果的估计、预测、展望、期望或意见，以及公司认为在特定情况下适当的其他假设，包括但不限于对各方能够及时以满意条款获得所需法院批准的假设；各方能够及时满足成交的其他条件以及完成安排的假设；以及其他与实施安排所需步骤相关的期望和假设。尽管公司相信这些前瞻性声明所产生的期望是基于有效和合理的基础和假设，但这些前瞻性声明本质上受到重要风险和不确定性的影响，其中许多超出了公司的控制，因此实际结果可能与这些前瞻性声明中披露或暗示的结果有显著差异。可能导致实际结果和未来事件与当前表达的期望显著不同的重要风险和不确定性包括但不限于：安排可能无法按照当前设想的相同条款和条件或时间完成，甚至可能根本无法完成，原因可能包括未能及时获得或满足所需的法院批准和其他成交条件，或其他原因；买方完成与安排相关的预期债务融资的能力；公司未能实现与 CVR 相关的任何里程碑；围绕安排的不确定性可能对公司保留客户、商业伙伴和关键员工产生不利影响；第三方提出收购提案的可能性；与税务事项相关的风险；公司开展的业务固有的其他风险以及超出其控制范围的因素，这些因素可能对公司或其完成安排的能力产生重大不利影响；以及一般经济条件，包括关税的潜在影响。
</div>For additional risks and uncertainties about the Company’s business, please see the “Financial Risk Management” and “Risk Factors” sections of the Company’s 2024 annual management and discussion analysis, which is available under the Company’s issuer profile on SEDAR+ at www.sedarplus.ca, and the section “Risk Factors” under the heading “Key Information” of the Company’s Form 20-F, which is available under the Company’s issuer profile on EDGAR at https://www.sec.gov/edgar/search. Readers should carefully consider the matters set forth in the section entitled “Risk Factors.” Readers are cautioned that the foregoing list of factors is not exhaustive and undue reliance should not be placed on Forward-Looking Statements. As a result, readers are advised that actual results may differ materially from expected results. Unless otherwise required by applicable securities laws, the Company expressly disclaims any intention, and assumes no obligation to update or revise any Forward-Looking Statements whether as a result of new information, future events or otherwise.
<div class="lb-trans">有关公司业务的其他风险和不确定性，请参见公司 2024 年年度管理和讨论分析中的 “财务风险管理” 和 “风险因素” 部分，该分析可在公司在 SEDAR+ 上的发行人资料中找到，网址为 www.sedarplus.ca，以及公司 20-F 表格中 “关键信息” 标题下的 “风险因素” 部分，该表格可在公司在 EDGAR 上的发行人资料中找到，网址为 https://www.sec.gov/edgar/search。读者应仔细考虑 “风险因素” 部分所列事项。读者需注意，前述因素列表并不详尽，且不应过度依赖前瞻性声明。因此，读者被告知，实际结果可能与预期结果存在重大差异。除非适用的证券法另有要求，公司明确声明不打算，也不承担更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。
</div>For further information, please contact:
<div class="lb-trans">如需更多信息，请联系：
</div>Theratechnologies Inc.
<div class="lb-trans">Theratechnologies Inc.
</div>Investor inquiries:
<div class="lb-trans">投资者咨询：
</div>Philippe Dubuc
<div class="lb-trans">Philippe Dubuc
</div>Senior Vice President and Chief Financial Officer
<div class="lb-trans">高级副总裁兼首席财务官
</div>pdubuc@theratech.com
<div class="lb-trans">pdubuc@theratech.com
</div>438-315-6608
<div class="lb-trans">438-315-6608
</div>Media inquiries:
<div class="lb-trans">媒体咨询：
</div>Julie Schneiderman
<div class="lb-trans">Julie Schneiderman
</div>Senior Director, Communications &amp; Corporate Affairs
<div class="lb-trans">高级总监，传播与企业事务
</div>communications@theratech.com
<div class="lb-trans">communications@theratech.com
</div>514-336-7800
<div class="lb-trans">514-336-7800
</div>Future Pak
<div class="lb-trans">Future Pak
</div>Investors and media may contact media@futurepak.com.
<div class="lb-trans">投资者和媒体可联系 media@futurepak.com。
</div><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU9ERTVNeU0zTVRRME16ZzNJekl3T0RNek9ETT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTUyODE5MyM3MTQ0Mzg3IzIwODMzODM="/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmRhMGMzNGYtOGY2Yi00OWVkLTk4NmQtNTQ3NmRiMTE3MzBjLTEwOTQ5NTQtMjAyNS0wOS0xMi1lbg==/tiny/Theratechnologies.png" alt="" original-src="https://ml.globenewswire.com/media/ZmRhMGMzNGYtOGY2Yi00OWVkLTk4NmQtNTQ3NmRiMTE3MzBjLTEwOTQ5NTQtMjAyNS0wOS0xMi1lbg==/tiny/Theratechnologies.png"/>

Theratechnologies 股东批准了拟议的安排计划，该计划将由 Future Pak 收购 | THTX 股票新闻